Psyched Wellness Provides Comprehensive Investor Update
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) has completed an initial pilot run of a new 4 oz dietary supplement shot through its US subsidiary, AME Wellness Inc., in collaboration with Zerkalo
The pilot program aims to beta test the shot with select consumers to gather feedback on taste, effects, and marketing data. The company will also evaluate its website, third-party logistics, and shipping processes to ensure proper fulfillment capabilities before the product launch.
CEO Jeff Stevens expressed excitement about this development phase of the new dietary supplement shot, praising Zerkalo's brand development efforts. The company plans to expand its route-to-market partnerships nationwide for their product line.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) ha completato un primo ciclo pilota di un nuovo integratore alimentare da 4 oz attraverso la sua filiale statunitense, AME Wellness Inc., in collaborazione con Zerkalo.
Il programma pilota ha l'obiettivo di testare il prodotto con consumatori selezionati per raccogliere feedback su gusto, effetti e dati di marketing. L'azienda valuterà anche il proprio sito web, la logistica di terze parti e i processi di spedizione per garantire adeguate capacità di evasione degli ordini prima del lancio del prodotto.
Il CEO Jeff Stevens ha espresso entusiasmo per questa fase di sviluppo del nuovo integratore alimentare, lodando gli sforzi di sviluppo del marchio di Zerkalo. L'azienda prevede di espandere le proprie partnership per l'accesso al mercato a livello nazionale per la propria linea di prodotti.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) ha completado un primer ciclo piloto de un nuevo shot de suplemento dietético de 4 oz a través de su subsidiaria en EE. UU., AME Wellness Inc., en colaboración con Zerkalo.
El programa piloto tiene como objetivo probar el shot con consumidores seleccionados para recopilar comentarios sobre el sabor, los efectos y los datos de marketing. La empresa también evaluará su sitio web, la logística de terceros y los procesos de envío para garantizar capacidades adecuadas de cumplimiento antes del lanzamiento del producto.
El CEO Jeff Stevens expresó su entusiasmo por esta fase de desarrollo del nuevo shot de suplemento dietético, elogiando los esfuerzos de desarrollo de marca de Zerkalo. La empresa planea expandir sus asociaciones para llegar al mercado a nivel nacional para su línea de productos.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF)는 미국 자회사인 AME Wellness Inc.와 협력하여 새로운 4 oz 다이어트 보충제 샷의 초기 파일럿 런을 완료했습니다.
파일럿 프로그램은 선택된 소비자와 함께 샷을 베타 테스트하여 맛, 효과 및 마케팅 데이터에 대한 피드백을 수집하는 것을 목표로 합니다. 회사는 또한 제품 출시 전에 적절한 이행 능력을 보장하기 위해 웹사이트, 제3자 물류 및 배송 프로세스를 평가할 것입니다.
CEO 제프 스티븐스는 새로운 다이어트 보충제 샷의 개발 단계에 대한 기대감을 표명하며, Zerkalo의 브랜드 개발 노력을 칭찬했습니다. 회사는 자사의 제품 라인을 위해 전국적으로 시장 접근 파트너십을 확장할 계획입니다.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) a achevé un premier cycle pilote d'un nouveau shot de complément alimentaire de 4 oz par l'intermédiaire de sa filiale américaine, AME Wellness Inc., en collaboration avec Zerkalo.
Le programme pilote vise à tester le shot avec des consommateurs sélectionnés afin de recueillir des retours sur le goût, les effets et les données marketing. L'entreprise évaluera également son site web, sa logistique tierce et ses processus d'expédition pour garantir des capacités d'exécution appropriées avant le lancement du produit.
Le PDG Jeff Stevens a exprimé son enthousiasme pour cette phase de développement du nouveau shot de complément alimentaire, louant les efforts de développement de marque de Zerkalo. L'entreprise prévoit d'élargir ses partenariats d'accès au marché à l'échelle nationale pour sa gamme de produits.
Psyched Wellness (CSE: PSYC) (OTCQB: PSYCF) hat einen ersten Pilotlauf eines neuen 4 oz Nahrungsergänzungsmittels durch ihre US-Tochtergesellschaft AME Wellness Inc. in Zusammenarbeit mit Zerkalo abgeschlossen.
Das Pilotprogramm zielt darauf ab, den Shot mit ausgewählten Verbrauchern zu testen, um Feedback zu Geschmack, Wirkung und Marketingdaten zu sammeln. Das Unternehmen wird auch seine Website, die Logistik von Drittanbietern und die Versandprozesse bewerten, um sicherzustellen, dass die Erfüllungskapazitäten vor dem Produktlaunch ordnungsgemäß sind.
CEO Jeff Stevens äußerte sich begeistert über diese Entwicklungsphase des neuen Nahrungsergänzungsmittels und lobte die Markenentwicklungsbemühungen von Zerkalo. Das Unternehmen plant, seine Marktzugangs-Partnerschaften landesweit für seine Produktlinie auszubauen.
- Successful completion of initial pilot run for new dietary supplement shot product
- Strategic partnership with Zerkalo for product development
- Expansion of distribution network in progress
- Product still in testing phase with no confirmed launch date
- Revenue generation from new product not yet established
Toronto, Ontario--(Newsfile Corp. - April 10, 2025) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom, is pleased to announce that its US subsidiary, AME Wellness Inc., working with its advisors, Zerkalo LLC, have completed an initial pilot run of our new dietary supplement in form of a 4 oz shot. The purpose of this pilot run is to beta test the shot with a select target group of consumers and gather feedback on the taste, the effect, and marketing data relating to the product. As part of this process, the Company will stress test its website, 3pl and shipping process to ensure that its fulfilment capabilities are in place in advance of the product launch.
"We are very excited to share this next phase in the development of our new dietary supplement shot," says, Jeff Stevens, CEO of the Company. "Zerkalo, our partners in the brand development have done an excellent job building this product and we look forward to sharing it in full, when the team is ready to launch."
Psyched Wellness will be growing their route-to-market partnerships, throughout the nation. If you are interested in distributing/listing Calm, please reach out to sales@psyched-wellness.com.
For further information, please contact:
Jeffrey Stevens
Chief Executive Officer
Psyched Wellness Ltd.
Tel: 647-400-8494
Email: jstevens@psyched-wellness.com
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to researching and producing consumer packaged goods products derived from our proprietary extract of the Amanita Muscaria mushroom, AME-1.
Cautionary Statement Regarding Forward-Looking Information
This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products and secure long-term manufacturing contract; the sufficiency of current production run for AME-1 and Calm; the success of Zerkalo in developing new dietary supplement; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company's ability to continue as a going concern; the Company's ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company's activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company's operations; competition within the market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247997
FAQ
What is the latest product development announcement from Psyched Wellness (PSYCF)?
What is the purpose of PSYCF's pilot program for their new supplement shot?
How is Psyched Wellness (PSYCF) planning to distribute their new supplement shot?
What role does Zerkalo play in Psyched Wellness's new product development?
